Profil bibliographique

Hajime Kikuchi

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

92Publications signalées

747Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentSeaweed-derived Bioactive Compounds

Publications récentes

Accès ouvert 2026 articleOpenAlex

Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study

Hiroshi Yokouchi, Hiroshi Nishihara, Yoshiyuki Kenmotsu, Kosuke Tsuji et autres

0 citationsImmunoTargets and Therapy

Accès ouvert 2026 articleOpenAlex

Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes

Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo et autres

0 citationsCancer Science

2026 conference-abstractOpenAlex

Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).

Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

A Case of Pure Red Cell Aplasia After Immune Checkpoint Inhibitor Therapy for Squamous Cell Lung Cancer

Toshihiro Kuroki, Hajime Kikuchi, Yukika Odani, Masafumi Ikezawa et autres

0 citationsHaigan

Accès ouvert 2026 articleOpenAlex

Optimal combination of heart and lung dose parameters in radiotherapy for locally advanced non-small cell lung carcinoma: a multicenter retrospective study

Tomohiko Miyazaki, Koichi Yasuda, Hiroshi Taguchi, Hideki Minatogawa et autres

0 citationsJournal of Radiation Research

Accès ouvert 2026 articleOpenAlex

85P Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301

O. Fumihiko, H. Tanaka, K. Onodera, R. Morita et autres

0 citationsESMO Open

Accès ouvert 2026 articleOpenAlex

Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis

Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, Yuki Takeyasu et autres

0 citationsJTO Clinical and Research Reports

Accès ouvert 2025 articleOpenAlex

Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301

Fumihiko Okumura, Katsuhiro Onodera, Ryo Morita, Minehiko Inomata et autres

0 citationsTranslational Lung Cancer Research

Accès ouvert 2025 articleOpenAlex

Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis

Yuriko Ishida, Shirô Watanabe, Jun Sakakibara‐Konishi, Yasuyuki Ikezawa et autres

1 citationJapanese Journal of Radiology

2025 conference-abstractOpenAlex

Prognostic significance of VISTA expression in patients with malignant pleural mesothelioma treated with nivolumab: Results of a retrospective multi-institutional analysis (HOT1901).

Hiroshi Yokouchi, Hiroshi Nishihara, Yoshiyuki Kenmotsu, Kosuke Tsuji et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2025 articleOpenAlex

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Toshiya Fujisaki, Eisaku Miyauchi, Gen Kida, Yu Miura et autres

4 citationsLung Cancer

Accès ouvert 2025 articleOpenAlex

Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy

Daisuke Morinaga, Jun Sakakibara‐Konishi, Yasutaka Kawai, Yumi Morinaga et autres

1 citationRespiratory Investigation

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.